LEMD1-AS1: A Potential Drug Target and Biomarker (G284576)

Target Name: LEMD1-AS1

NCBI ID: G284576

LEMD1-AS1

Other Name(s): LEMD1 antisense RNA 1

LEMD1-AS1: A Potential Drug Target and Biomarker

LEMD1-AS1 is a non-coding RNA molecule that has been identified as an antisense RNA 1 in the LEMD1 gene, which is located on chromosome 18q22. This RNA molecule has been shown to play a role in the regulation of gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of LEMD1-AS1 as an antisense RNA 1 has significant implications for the development of new therapeutics and biomarkers for these diseases. By targeting LEMD1-AS1, researchers may be able to improve disease treatment outcomes and develop new diagnostic tools.

Antisense RNA 1 and its function

Antisense RNA 1 (AS1) is a class of RNA molecule that is derived from a non-coding RNA template and has the ability to interact with specific mRNAs to either enhance or inhibit their translation into proteins. These interactions between AS1 and target mRNAs are often accompanied by changes in gene expression levels and can be used as a drug target or a biomarker.

LEMD1-AS1 is a non-coding RNA molecule that has been shown to interact with the protein encoded by the LEMD1 gene, which is located on chromosome 18q22. The LEMD1 gene is known to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The interaction between LEMD1-AS1 and LEMD1 protein has been shown to play a role in the regulation of gene expression and can potentially serve as a drug target or biomarker.

Drug targeting LEMD1-AS1

Targeting LEMD1-AS1 as a drug target has the potential to improve the treatment outcomes for various diseases. For example, LEMD1-AS1 has been shown to be involved in the regulation of the growth and survival of cancer cells, which could be a potential target for anti-cancer therapeutics.

In addition, LEMD1-AS1 has also been shown to be involved in the regulation of the immune response, which could make it a potential target for anti-inflammatory therapeutics.

Biomarker development

The development of biomarkers for diseases can have a significant impact on diagnosis and treatment outcomes. The identification of LEMD1-AS1 as an antisense RNA 1 with potential drug targeting properties has the potential to generate new biomarkers for various diseases.

For example, LEMD1-AS1 could be used as a biomarker for cancer, as its interaction with the LEMD1 gene has been shown to play a role in the regulation of gene expression in cancer cells.

In addition, LEMD1-AS1 could also be used as a biomarker for neurodegenerative diseases, as its interaction with the LEMD1 gene has been shown to play a role in the regulation of gene expression in these diseases.

Conclusion

LEMD1-AS1 is a non-coding RNA molecule that has been identified as an antisense RNA 1 in the LEMD1 gene. Its interaction with the protein encoded by the LEMD1 gene has been shown to play a role in the regulation of gene expression and has the potential to serve as a drug target or a biomarker for various diseases. Further research is needed to fully understand the role of LEMD1-AS1 in disease progression and to develop new therapeutics and biomarkers for these diseases.

Protein Name: LEMD1 Antisense RNA 1

The "LEMD1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LEMD1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets